1066 related articles for article (PubMed ID: 19016372)
21. Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells.
Petrini I; Pacini S; Petrini M; Fazzi R; Trombi L; Galimberti S
Eur J Clin Invest; 2009 Sep; 39(9):813-8. PubMed ID: 19522834
[TBL] [Abstract][Full Text] [Related]
22. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
[TBL] [Abstract][Full Text] [Related]
23. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
24. Impaired function of gamma-delta lymphocytes in melanoma patients.
Petrini I; Pacini S; Galimberti S; Taddei MR; Romanini A; Petrini M
Eur J Clin Invest; 2011 Nov; 41(11):1186-94. PubMed ID: 22775565
[TBL] [Abstract][Full Text] [Related]
25. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K
Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955
[TBL] [Abstract][Full Text] [Related]
26. Modulation of innate immunity by IL-18.
Li W; Yamamoto H; Kubo S; Okamura H
J Reprod Immunol; 2009 Dec; 83(1-2):101-5. PubMed ID: 19853308
[TBL] [Abstract][Full Text] [Related]
27. Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens.
Iwasaki M; Tanaka Y; Kobayashi H; Murata-Hirai K; Miyabe H; Sugie T; Toi M; Minato N
Eur J Immunol; 2011 Feb; 41(2):345-55. PubMed ID: 21268005
[TBL] [Abstract][Full Text] [Related]
28. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
[TBL] [Abstract][Full Text] [Related]
29. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
30. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].
Li Z; Tang J; Sun L; Ye Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710
[TBL] [Abstract][Full Text] [Related]
31. [Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].
Li SP; Urban FA; Macgregor JN; Hughes DP; McDonagh KT
Ai Zheng; 2004 Nov; 23(11 Suppl):1370-5. PubMed ID: 15566639
[TBL] [Abstract][Full Text] [Related]
32. Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study.
Chan B; Lee W; Hu CX; Ng P; Li KW; Lo G; Ho G; Yeung DW; Woo D
Cytotherapy; 2003; 5(1):46-54. PubMed ID: 12745587
[TBL] [Abstract][Full Text] [Related]
33. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
Delirezh N; Moazzeni SM; Shokri F; Shokrgozar MA; Atri M; Kokhaei P
Cell Immunol; 2009; 257(1-2):23-31. PubMed ID: 19306994
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
35. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
[TBL] [Abstract][Full Text] [Related]
36. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
37. Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation.
Takahara M; Miyai M; Tomiyama M; Mutou M; Nicol AJ; Nieda M
J Leukoc Biol; 2008 Mar; 83(3):742-54. PubMed ID: 18156189
[TBL] [Abstract][Full Text] [Related]
38. Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis.
Hiraki A; Ono T; Tanaka M; Kiura K; Ueoka H; Kawai H; Harada M; Nakayama E; Noguchi Y
Anticancer Res; 2001; 21(4A):2561-7. PubMed ID: 11724322
[TBL] [Abstract][Full Text] [Related]
39. gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.
Braza MS; Caraux A; Rousset T; Lafaye de Micheaux S; Sicard H; Squiban P; Costes V; Klein B; Rossi JF
J Immunol; 2010 Jan; 184(1):134-40. PubMed ID: 19949101
[TBL] [Abstract][Full Text] [Related]
40. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
